Pharmaxis Welcomes Green Light to Progress to Phase 2 Bone Marrow Cancer Trial
Release Date: 05/10/2021 12:15pm
Pharmaxis CEO Gary Phillips speaks to Proactive Investors following the news the Company has been cleared to progress its bone marrow cancer trial to a phase 2 dose expansion phase. It follows further positive results of data analysis from the phase 1c clinical trial of its drug PXS‐5505.
Watch the interview here.
Categories: Video Content